FONDO-LOW
Randomized, Double-Blind Study of FOND (Fosaprepitant, ONdansetron, Dexamethasone) Plus Either Olanzapine 2.5 Mg Versus 5 Mg for the Prevention of Chemotherapy Induced Nausea and Vomiting in Patients Receiving High-dose Melphalan Conditioning: the FONDO-LOW Study
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 172 patients (estimated)
- Sponsors
- Augusta University Medical Center
- Tags
- Antipsychotic, Pre-Autologous Stem Cell Transplant, Randomization
- Trial Type
- Supportive
- Last Update
- 8 months ago
- SparkCures ID
- 1994
- NCT Identifier
- NCT06588413
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.